Brian M. Culley - Jun 30, 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Signature
/s/ Brian M. Culley
Stock symbol
LCTX
Transactions as of
Jun 30, 2022
Transactions value $
-$8,442
Form type
4
Date filed
6/30/2022, 05:57 PM
Previous filing
Apr 4, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares, no par value Options Exercise +15.5K +15.8% 113K Jun 30, 2022 Direct F1, F2
transaction LCTX Common Shares, no par value Tax liability -$8.44K -5.34K -4.72% $1.58 108K Jun 30, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Restricted Stock Units Options Exercise $0 -15.5K -100% $0.00* 0 Jun 30, 2022 Common Shares 15.5K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis.
F2 Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report.
F3 Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
F4 The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter.